Oncotalks hematology videos and news

EHA 2019 Srdan Verstovsek, MD, PhD - educational session MPN

Related items

EHA 2019 Prof. James Bussel, MD - PHYSICIANS' PERCEPTIONS ON CAUSES OF PRIMARY AND SECONDARY ITP AND LEADING CAUSES OF MISDIAGNOSIS: RESULTS FROM THE ITP WORLD IMPACT SURVEY (I-WISH)

EHA 2019 Prof. James Bussel, MD - PHYSICIANS' PERCEPTIONS ON CAUSES OF PRIMARY AND SECONDARY ITP AND LEADING CAUSES OF MISDIAGNOSIS: RESULTS FROM THE ITP WORLD IMPACT SURVEY (I-WISH)

Prof. James Bussel, MD from the Well Cornel Medicine, New York, USA is commenting on the abstract PHYSICIANS' PERCEPTIONS ON CAUSES OF PRIMARY AND SECONDARY ITP AND LEADING CAUSES OF MISDIAGNOSIS: RESULTS FROM THE ITP WORLD IMPACT SURVEY (I-WISH) which was presented at EHA 2019 in Amsterdam.Reference: EHA Library. Bussel J. Jun 14, 2019; 266511Link to abstract https://library.ehaweb.org/eha/2019/24th/266511/j.bussel.physicians.perceptions.on.causes.of.primary.and.secondary.itp.and.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dmisdiagnosis%3A+results%2Bitp+world+impact+survey+%28i-wish%29
Lithuania , Albania
00:06:09
ESMO 2019 Valentina Guarneri, MD, PhD; Overall survival (OS) results of the Phase III MONALEESA-3 trial

ESMO 2019 Valentina Guarneri, MD, PhD; Overall survival (OS) results of the Phase III MONALEESA-3 trial

Valentina Guarneri, MD, PhD from the University of Padua, Padua, Italy is commenting on the abstract: LBA7_PR - Overall survival (OS) results of the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)
ESMO , Kisqali Channel , Latvia , Lithuania , Estonia , Hungary , Albania
00:03:29
EHA 2019 Jeroen Janssen, MD, PhD

EHA 2019 Jeroen Janssen, MD, PhD

Jeroen Janssen MD, PhD from the Amsterdam UMC, Amsterdam, The Netherlands is commenting on the abstract COMBINATION THERAPY USING ASCIMINIB PLUS IMATINIB (IMA) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA (CML) & COMBINATION OF ASCIMINIB PLUS NILOTINIB (NIL) OR DASATINIB (DAS) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA Reference: EHA Library. Kew S. Jun 15, 2019; 267467Link to abstract: https://library.ehaweb.org/eha/2019/24th/267467/sam.kew.combination.of.asciminib.plus.nilotinib.28nil29.or.dasatinib.28das29.in.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dasciminib
EHA , Latvia , Lithuania , Estonia , Albania
00:05:04
EHA 2019 Prof. Michael Pfeilstöcker, MD

EHA 2019 Prof. Michael Pfeilstöcker, MD

Prof. Michael Pfeilstöcker, MD from the Heinrich-Heine University Hospital, Düsseldorf, Germany is commenting on 2 publications LONG-TERM OVERUSE OF CORTICOSTEROIDS IN THE REAL-WORLD TREATMENT OF PATIENTS WITH IMMUNE THROMBOCYTOPENIA IN THE US EXPLORYS AND MARKETSCAN DATABASES Reference: EHA Library. Bussel J. Jun 14, 2019; 266509Link to abstract: https://library.ehaweb.org/eha/2019/24th/266509/j.bussel.long-term.overuse.of.corticosteroids.in.the.real-world.treatment.of.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3DLONG-TERM+OVERUSE+OF+CORTICOSTEROIDS+IN+THE+REAL-WORLD+TREATMENT+OF+PATIENTS+WITH+IMMUNE+THROMBOCYTOPENIA+IN+THE+US+EXPLORYS+AND+MARKETSCAN+DATABASESDIFFERENCES IN PERCEPTIONS ON TREATMENT APPROACHES BETWEEN PHYSICIANS AND ITP PATIENTS: RESULTS FROM THE ITP WORLD IMPACT SURVEY (I-WISH) both presented at EHA 2019 in AmsterdamReference: EHA Library. Kruse A. Jun 14, 2019; 266510Link to abstract: https://library.ehaweb.org/eha/2019/24th/266510/alexandra.kruse.differences.in.perceptions.on.treatment.approaches.between.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dresults%2Bitp+world+impact+survey+%28i-wish
EHA , Latvia , Lithuania , Estonia , Albania
00:05:30